• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局灶性扩增与 Ta 期膀胱癌的高级别和复发相关。

Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma.

机构信息

Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, SE-75185 Uppsala, Sweden.

出版信息

Int J Cancer. 2010 Mar 15;126(6):1390-402. doi: 10.1002/ijc.24954.

DOI:10.1002/ijc.24954
PMID:19821490
Abstract

Urinary bladder cancer is a heterogeneous disease with tumors ranging from papillary noninvasive (stage Ta) to solid muscle infiltrating tumors (stage T2+). The risk of progression and death for the most frequent diagnosed type, Ta, is low, but the high incidence of recurrences has a significant effect on the patients' quality of life and poses substantial costs for health care systems. Consequently, the purpose of this study was to search for predictive factors of recurrence on the basis of genetic profiling. A clinically well characterized cohort of Ta bladder carcinomas, selected by the presence or absence of recurrences, was evaluated by an integrated analysis of DNA copy number changes and gene expression (clone-based 32K, respectively, U133Plus2.0 arrays). Only a few chromosomal aberrations have previously been defined in superficial bladder cancer. Surprisingly, the profiling of Ta tumors with a high-resolution array showed that DNA copy alterations are relatively common in this tumor type. Furthermore, we observed an overrepresentation of focal amplifications within high-grade and recurrent cases. Known (FGFR3, CCND1, MYC, MDM2) and novel candidate genes were identified within the loci. For example, MYBL2, a nuclear transcription factor involved in cell-cycle progression; YWHAB, an antiapoptotic protein; and SDC4, an important component of focal adhesions represent interesting candidates detected within two amplicons on chromosome 20, for which DNA amplification correlated with transcript up-regulation. The observed overrepresentation of amplicons within high-grade and recurrent cases may be clinically useful for the identification of patients who will benefit from a more aggressive therapy.

摘要

膀胱癌是一种异质性疾病,肿瘤从乳头状非浸润性(Ta 期)到实性肌肉浸润性肿瘤(T2+期)不等。最常见的诊断类型 Ta 的进展和死亡风险较低,但高复发率对患者的生活质量有重大影响,并对医疗保健系统造成巨大的经济负担。因此,本研究旨在根据基因谱寻找复发的预测因素。通过对存在或不存在复发的 Ta 膀胱癌进行 DNA 拷贝数变化和基因表达的综合分析(分别基于克隆的 32K 和 U133Plus2.0 阵列),对 Ta 膀胱癌进行了临床特征良好的队列评估。以前已经在表浅膀胱癌中定义了少数染色体异常。令人惊讶的是,使用高分辨率阵列对 Ta 肿瘤进行的分析表明,这种肿瘤类型中 DNA 拷贝改变相对常见。此外,我们观察到高级别和复发性病例中局灶性扩增的过度表达。在已知(FGFR3、CCND1、MYC、MDM2)和新的候选基因中,在这些基因座内鉴定到了候选基因。例如,参与细胞周期进展的核转录因子 MYBL2、抗凋亡蛋白 YWHAB 和焦点黏附的重要组成部分 SDC4,是在 20 号染色体的两个扩增子中检测到的有趣候选基因,其 DNA 扩增与转录上调相关。高级别和复发性病例中扩增子的过度表达可能对识别将从更积极治疗中获益的患者具有临床意义。

相似文献

1
Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma.局灶性扩增与 Ta 期膀胱癌的高级别和复发相关。
Int J Cancer. 2010 Mar 15;126(6):1390-402. doi: 10.1002/ijc.24954.
2
High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.基于高分辨率芯片的膀胱癌比较基因组杂交研究确定小鼠双微体4(MDM4)为一个独立于MDM2和TP53的扩增靶点。
Clin Cancer Res. 2008 May 1;14(9):2527-34. doi: 10.1158/1078-0432.CCR-07-4129.
3
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.PIK3CA基因改变在膀胱癌中很常见,且与非肌层浸润性肿瘤复发率降低相关。
Mol Carcinog. 2015 Jul;54(7):566-76. doi: 10.1002/mc.22125. Epub 2013 Dec 18.
4
CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.CDKN2A 纯合缺失与 FGFR3 突变型尿路上皮膀胱癌的肌肉浸润有关。
J Pathol. 2012 Jul;227(3):315-24. doi: 10.1002/path.4017. Epub 2012 May 8.
5
Beta-catenin mutations correlate with over expression of C-myc and cyclin D1 Genes in bladder cancer.β-连环蛋白突变与膀胱癌中C-myc和细胞周期蛋白D1基因的过表达相关。
J Urol. 2002 Nov;168(5):2220-6. doi: 10.1016/S0022-5347(05)64359-5.
6
Allelic deletions of cell growth regulators during progression of bladder cancer.膀胱癌进展过程中细胞生长调节因子的等位基因缺失。
Cancer Res. 2000 Dec 1;60(23):6623-9.
7
Chromosome 8 numerical aberration and C-MYC copy number gain in bladder cancer are linked to stage and grade.膀胱癌中8号染色体数目畸变及C-MYC拷贝数增加与分期和分级相关。
Anticancer Res. 2001 Sep-Oct;21(5):3167-73.
8
Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.17号染色体多体在膀胱移行细胞癌中的作用:HER2/neu表达的免疫组化研究及c-erbB-2基因与17号染色体的荧光原位杂交分析
Int J Surg Pathol. 2009 Jun;17(3):198-205. doi: 10.1177/1066896909333415.
9
Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.影响血吸虫相关性膀胱癌中p53调控通路的改变。
Clin Cancer Res. 1997 Apr;3(4):531-6.
10
Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer.MDM2、MDM4、FGFR1和FGFR3的基因组畸变与涎腺癌患者的不良预后相关。
J Oral Pathol Med. 2016 Aug;45(7):500-9. doi: 10.1111/jop.12394. Epub 2015 Dec 14.

引用本文的文献

1
Bladder Cancer: Role of Circular RNAs in Oncogenesis, Tumor Suppression, and Therapeutic Target Identification.膀胱癌:环状RNA在肿瘤发生、肿瘤抑制及治疗靶点识别中的作用
Cancer Genomics Proteomics. 2025 Sep-Oct;22(5):654-682. doi: 10.21873/cgp.20528.
2
Integrating analysis of multi-omics summary data identifies novel plasma protein biomarkers and drug targets for bladder cancer.多组学汇总数据的整合分析鉴定出膀胱癌新的血浆蛋白生物标志物和药物靶点。
Discov Oncol. 2025 May 2;16(1):660. doi: 10.1007/s12672-025-02476-5.
3
Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration.
综合转录组分析确定MYBL2是骨肉瘤预后不良的标志物以及免疫浸润的泛癌标志物。
Genes Dis. 2023 Jul 11;11(3):101004. doi: 10.1016/j.gendis.2023.04.035. eCollection 2024 May.
4
Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.在侵袭性激素敏感性前列腺癌中 MYBL2 表达增加。
Mol Oncol. 2022 Dec;16(22):3994-4010. doi: 10.1002/1878-0261.13314. Epub 2022 Oct 2.
5
Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.在日本晚期实体瘤患者中进行不可逆成纤维细胞生长因子受体 1-4 抑制剂 futibatinib 的 I 期研究。
Cancer Sci. 2023 Feb;114(2):574-585. doi: 10.1111/cas.15486. Epub 2022 Dec 4.
6
Intricate crosstalk between MYB and noncoding RNAs in cancer.MYB与非编码RNA在癌症中的复杂相互作用。
Cancer Cell Int. 2021 Dec 7;21(1):653. doi: 10.1186/s12935-021-02362-4.
7
Novel Ferroptosis-Related Multigene Prognostic Models for Patients with Bladder Cancer.膀胱癌患者新型铁死亡相关多基因预后模型
Int J Gen Med. 2021 Nov 23;14:8651-8666. doi: 10.2147/IJGM.S339996. eCollection 2021.
8
Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer.黏附素 4 作为癌症发病机制中的一个因素和治疗靶点。
Biomolecules. 2021 Mar 26;11(4):503. doi: 10.3390/biom11040503.
9
Urinary Cell-Free DNA in Bladder Cancer Detection.膀胱癌检测中的尿液游离DNA
Diagnostics (Basel). 2021 Feb 14;11(2):306. doi: 10.3390/diagnostics11020306.
10
Association between B- proto-oncogene and the development of malignant tumors.B原癌基因与恶性肿瘤发生之间的关联。
Oncol Lett. 2021 Feb;21(2):166. doi: 10.3892/ol.2021.12427. Epub 2021 Jan 4.